DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Intravenous Immunoglobulin (IVIG) in Lung Transplantation

Information source: Arcasoy, Selim, M.D.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypogammaglobulinemia; Lung Transplantation

Intervention: Intravenous immunoglobulin (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: Arcasoy, Selim, M.D.

Official(s) and/or principal investigator(s):
Selim M Arcasoy, M.D., Principal Investigator, Affiliation: Columbia University


The purpose of this study is to determine if intravenous immunoglobulin (IVIG) can prevent bacterial infections in lung transplant patients with low serum levels of immunoglobulin.

Clinical Details

Official title: IVIG for Acquired Immunodeficiency in Lung Transplant Patients

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: Bacterial infections

Secondary outcome:

Other infections

Hospital admissions

Antibiotic use


Side effects

Pulmonary function



Detailed description: An increased risk of infection despite intensive antimicrobial prophylaxis is a well-recognized complication of lung transplantation. Recent evidence suggests that immunosuppressive therapy after solid organ transplantation may lead to humoral immunodeficiency due to hypogammaglobulinemia (HGG). In lung transplant recipients with HGG, IVIG therapy offers the potential to significantly decrease the incidence and severity of infections, thereby reducing morbidity and potentially mortality. Comparison: The investigators are conducting a randomized clinical trial of IVIG versus placebo for lung transplant patients with severe HGG to see if IVIG decreases the number of bacterial infections in these patients.


Minimum age: 12 Years. Maximum age: 75 Years. Gender(s): Both.


Inclusion Criteria:

- Lung transplant recipients >3 months after transplant surgery

- IgG < 500 mg/dL

- Stable medical regimen

Exclusion Criteria:

- Acute rejection

- Active infection

- Contraindication to IVIG

- Pregnancy

- Recent thrombotic event

Locations and Contacts

New York Presbyterian Hospital Lung Transplant Program, New York, New York 10032, United States
Additional Information

Starting date: June 2005
Last updated: June 18, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017